Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estándar de atención de primera línea basado en la inmunoterapia y tratamientos ablativos locales para pacientes oligometastásicos de cáncer de pulmón de células no pequeñas. (OliGRAIL)

4 de noviembre de 2026 actualizado por: Gustave Roussy, Cancer Campus, Grand Paris

Estándar de atención de primera línea basado en inmunoterapia y tratamientos ablativos locales para pacientes oligometastastásicos de cáncer de pulmón de células no pequeñas: un estudio aleatorizado, multicéntrico y de fase abierta de fase III

First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

124

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Caen, Francia, 14076
        • Reclutamiento
        • Centre François Baclesse
        • Contacto:
      • Lille, Francia, 59000
        • Reclutamiento
        • Centre Oscar Lambret
        • Contacto:
      • Lyon, Francia, 69000
        • Reclutamiento
        • Hospices Civils de Lyon (HCL)
        • Contacto:
      • Nice, Francia, 06001
        • Reclutamiento
        • CHU Nice
        • Contacto:
      • Nîmes, Francia, 30029
        • Reclutamiento
        • Institut de Cancérologie du Gard
        • Contacto:
      • Paris, Francia, 75014
        • Reclutamiento
        • Hôpital Paris Saint- Joseph
        • Contacto:
          • Charles NALTET
          • Número de teléfono: 01 44 12 37 52
          • Correo electrónico: cnaltet@ghpsj.fr
      • Tarbes, Francia, 65000
        • Reclutamiento
        • Polyclinique Ormeau
        • Contacto:
          • Pierre-Marie PIALAT
          • Número de teléfono: 05 62 93 59 29
          • Correo electrónico: dr.pialat@grop65.fr
    • Hauts-de-France
      • Creil, Hauts-de-France, Francia, 60100
        • Reclutamiento
        • Institut de Radiothérapie du Sud de l'Oise
        • Contacto:
        • Investigador principal:
          • Andres HUERTAS, MD
    • Provence-Alpes-Côte d'Azur Region
      • Avignon, Provence-Alpes-Côte d'Azur Region, Francia, 84000
        • Reclutamiento
        • Centre Sainte-Catherine
        • Contacto:
          • Nicolas POUREL, MD
          • Número de teléfono: +33 (0)4 90 27 60 28
          • Correo electrónico: n.pourel@isc84.org
        • Investigador principal:
          • Nicolas POUREL, MD
    • Île-de-France Region
      • Saint-Cloud, Île-de-France Region, Francia, 92210
        • Reclutamiento
        • Institut Curie
        • Contacto:
      • Villejuif, Île-de-France Region, Francia, 94805
        • Reclutamiento
        • Gustave Roussy
        • Investigador principal:
          • Antonin LÉVY, MD
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Histologically proven advanced synchronous oligometastatic stage IV NSCLC.
  • NSCLC patients eligible first line immunotherapy-based SoC according to the European Marketing Authorization.
  • PDL1 status available.
  • Metastases eligible to RLT according to the local multidisciplinary board (MTB): ≤5cm each in CT scan, excluding primary tumour.
  • Maximum 5 metastases in 3 organs (EORTC criteria), according to brain MRI and FDG-PET.
  • Symptomatic lesions requiring urgent palliative radiation, is permitted prior to randomization. These treated lesions should be counted towards the total number of metastases at the time of enrolment.
  • Clinically required brain metastases (BM) ablation (surgery and/or SBRT) is permitted and BM count within the total number of 5 lesions. The patient would then be randomized to treatment of their extracranial disease.
  • Acceptable organ function for RLT.
  • ECOG performance status (PS) 0-1.
  • Measurable lesions according to RECIST V1.1 on standard imaging.
  • Patient aged 18 or more.
  • Woman of childbearing potential must agree to use adequate contraception (implant type, vaginal ring, contraceptive pill, contraceptive patch, Intrauterine Device (IUD), etc.) for the duration of study participation and up to 6 months after completing treatment/therapy, in addition, male partners use a condom during this same period. Male patients must agree to use condom for the duration of study participation and up to 6 months after completing treatment/therapy.
  • Patients affiliated to the social security system.
  • Patient should understand, sign, and date the informed consent form written in French prior to any protocol-specific procedures performed.
  • Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits, and examinations including follow-up.

Exclusion Criteria:

  • Non-squamous NSCLC with targetable tumour mutations and approved first line targeted therapy (such as EGFR, ALK and ROS1).
  • Metastases not eligible to RLT: e.g. brainstem or diffuse serosal metastases (meningeal, pericardial, pleural, peritoneal, mesenteric) or that invades the gastrointestinal tract.
  • Brain metastases only, without extra-cerebral metastases.
  • Uncontrolled severe comorbidity, symptomatic interstitial lung disease or active infection.
  • Prior therapy with T-cell costimulation or immune checkpoint-targeted agents within 1 year.
  • Uncontrolled concomitant (<1-year) malignancy except adequately treated basal or squamous cell carcinoma of the skin, or in-situ carcinoma of any organ or in-situ melanoma of the skin.
  • Persons deprived of liberty by judicial or administrative decision.
  • Persons subject to a legal protection measure (guardianship, curatorship, safeguard of justice).
  • Persons not affiliated to a social security system or equivalent.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Experimental arm: RLT + SoC-based immunotherapy (+/- chemotherapy)

RLT of all metastatic sites should be administered within 3 months after randomization and should not delay SoC-based immunotherapy administration.

RLT of all metastatic sites. The possible RLT options will be SBRT, interventional radiology and/or minimally invasive surgery. Depending on the metastatic site, access and patient condition, the best RLT should be initially discussed in a case-to-case basis at the local multidisciplinary board (MTB).

The primary tumour and initially invaded lymph nodes should be treated during the maintenance phase. Curative-intent approach modalities (e.g. hypofractionated intensity-modulated thoracic radiation therapy or surgery) should be discussed at the local MTB.

Otros nombres:
  • SBRT
  • Radiología intervencional
  • Cirugía mínimamente invasiva

Current French SoC will be used. Main SoC-based immunotherapy includes:

  • Platinum-based chemotherapy combined with an anti PD-1 immunotherapy (pembrolizumab). Pemetrexed-platinum combinations may be used in non- squamous carcinoma, while paclitaxel-platinum combination is favoured in squamous carcinoma.
  • Anti PD-1 monotherapy if PD-L1 ≥ 50% is a possible alternative (pembrolizumab or atezolizumab or cemiplimab).

Other alternatives include nivolumab-ipilimumab-chemotherapy or durvalumab-tremelimumab-chemotherapy association. Bevacizumab is not allowed given possible interactions with RLT.

Maintenance/Immunotherapy alone will be pursued at the investigator's discretion according to the standard procedures (toxicity, progression, choice of the patient...).

Comparador activo: Control arm: SoC-based immunotherapy (+/- chemotherapy)

SoC-based immunotherapy (+/- chemotherapy) will be administered every 3 weeks

Current French SoC will be used. Main SoC-based immunotherapy includes:

  • Platinum-based chemotherapy combined with an anti PD-1 immunotherapy (pembrolizumab). Pemetrexed-platinum combinations may be used in non- squamous carcinoma, while paclitaxel-platinum combination is favoured in squamous carcinoma.
  • Anti PD-1 monotherapy if PD-L1 ≥ 50% is a possible alternative (pembrolizumab or atezolizumab or cemiplimab).

Other alternatives include nivolumab-ipilimumab-chemotherapy or durvalumab-tremelimumab-chemotherapy association. Bevacizumab is not allowed given possible interactions with RLT.

Maintenance/Immunotherapy alone will be pursued at the investigator's discretion according to the standard procedures (toxicity, progression, choice of the patient...).

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall Survival (OS).
Periodo de tiempo: From date of randomization up to two years after the randomization of the last patient or documented death.

Time from randomization to the date of documented death from any cause or last follow-up.

From date of randomization up to two years after the randomization of the last patient or documented death.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Progression-free survival (PFS) according to RECIST 1.1.
Periodo de tiempo: From date of randomization up to two years after the randomization of the last patient or documented death.

Time between the randomization date and the date of observation of a progression of the disease according to RECIST 1.1 or death of the patient (all causes combined) or date of last follow-up if the patient is alive without progression or lost to follow up.

From date of randomization up to two years after the randomization of the last patient or documented death.
immune Progression-free survival (iPFS) according to iRECIST.
Periodo de tiempo: From date of randomization up to two years after the randomization of the last patient or documented death.

Time between the randomization date and the date of observation of an progression of the disease according to iRECIST 1.1 or death of the patient (all causes combined) or date of last follow-up if the patient is alive without progression or lost to follow up.

From date of randomization up to two years after the randomization of the last patient or documented death.
Number of side effects measured by CTCAE V.5.
Periodo de tiempo: From date of randomization up to two years after the randomization of the last patient or documented death.

Acute/ late adverse events graded by CTCAE v5 (toxic death and serious adverse events) and their imputability to treatment.

From date of randomization up to two years after the randomization of the last patient or documented death.
EORTC Quality of Life Questionnaire-C30 (EORTC QLQ-C30).
Periodo de tiempo: From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.

The EORTC Quality of Life Questionnaire-C30 (EORTC QLQ-C30) contains 30 questions and assesses the quality of life of oncological patients multidimensionally over 10 subscales. All sub-scales and the 6 individual items have a score range from 0 to 100 points. A higher score represents better function and a higher quality of life. In the symptom subscale, however, a higher score represents a higher level of symptoms or problems.

From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.
EORTC Quality of Life Questionnaire Lung Cancer-specific-13 (QLQ-LC-13).
Periodo de tiempo: From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.

EORTC Quality of Life Questionnaire Lung Cancer-specific-13 (QLQ-LC-13) is a specific companion module used in conjunction with the EORTC QLQ-C30 and specifically developed for patients with Lung Cancer, and reliable in LC specific Qol assessment. The EORTC QLQ-LC13 comprises 13 item that measure lung cancer-related symptoms. Each items use the same 1-to-4 verbal response scale as the QLQ-C30 items, and domain scores are also transformed to a 0-to-100 metric. A higher score represents better function and a higher quality of life.

From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.
EuroQol-5D-5L Questionnaire (EQ-5D-5L).
Periodo de tiempo: From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.

The EuroQol-5D-5L Questionnaire (EQ-5D-5L) descriptive system of 5 health dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Index scores range from -0.59 to 1; 1 is the best possible health state. Negative values represent health states perceived as worse than dead, which is equal to 0. Used alongside the EQ-5D, the EQ visual analog scale (VAS) is a 20 cm VAS "assessing your own health today" with endpoints labeled "Best imaginable health state" (100) and "Worst imaginable health state" (0).

From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.
Clearance of circulating tumour DNA (ctDNA).
Periodo de tiempo: At the randomization, then Week 6 and Month 4 after randomization.

ctDNA assessed in plasma.

At the randomization, then Week 6 and Month 4 after randomization.
Economic evaluation.
Periodo de tiempo: From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.

Incremental cost per Quality-adjusted life year (QALY based on EQ-5D-5L measures), incremental net monetary benefit. Assess the cost-utility (cost per QALY) of RLT + immunotherapy-based SoC compared to immunotherapy-based SoC alone.

From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

9 de septiembre de 2025

Finalización primaria (Estimado)

1 de febrero de 2030

Finalización del estudio (Estimado)

1 de febrero de 2030

Fechas de registro del estudio

Enviado por primera vez

16 de enero de 2025

Primero enviado que cumplió con los criterios de control de calidad

18 de febrero de 2025

Publicado por primera vez (Actual)

21 de febrero de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

4 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 2023-503326-39-00
  • 2023/3729 (Otro identificador: CSET number (Gustave Roussy ID))
  • 2023 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir